Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538292 | 0.87 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1TP53MAPTKDM4E | |
| SCHEMBL31428582 | 0.86 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1TP53MAPTKDM4E | |
| SCHEMBL31428806 | 0.86 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1TP53MAPTKDM4E | |
| SCHEMBL31428597 | 0.86 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1TP53MAPTKDM4E | |
| SCHEMBL16621161 | 0.86 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1TP53MAPTKDM4E | |
| SCHEMBL24975631 | 0.86 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1TP53MAPTKDM4E | |
| SCHEMBL9907539 | 0.86 | ALDH1A1 (0.60) | ALDH1A1L3MBTL1TP53MAPTKDM4E | |
| SCHEMBL22349633 | 0.85 | MAPT (0.52) | ALDH1A1L3MBTL1MAPTKDM4EHPGD | |
| SCHEMBL20271627 | 0.85 | GAA (0.62) | ALDH1A1L3MBTL1TP53MAPTKDM4E | |
| SCHEMBL30049700 | 0.85 | GAA (0.62) | ALDH1A1L3MBTL1TP53MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | ALDH1A1 1799/4885L3MBTL1 3654/4885TP53 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.